PT Royal Prima (PRIM) Fundamentals 2026 — Revenue Analysis | SniperIQ
PT Royal Prima (PRIM) is a ID-listed Healthcare company in Medical - Care Facilities with a market capitalization of Rp331.1B, trading at Rp98.00 on the JKT. This SniperIQ fundamentals page covers PT Royal Prima's valuation, profitability (net margin -5.9%), revenue (Rp338.9B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is PT Royal Prima's market cap?
PT Royal Prima (PRIM) has a market capitalization of approximately Rp331.1B, trading at Rp98.00 on the JKT. Market cap moves with the live share price.
What is PT Royal Prima's P/E ratio?
PT Royal Prima's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is PT Royal Prima?
PT Royal Prima runs a net profit margin of -5.9%, a gross margin of 21.5%, and an operating margin of -6.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does PT Royal Prima generate?
PT Royal Prima reported revenue of Rp338.9B for fiscal year 2025, with net income of -Rp21.8B and earnings per share (EPS) of -6.46. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does PT Royal Prima pay a dividend?
PT Royal Prima does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is PT Royal Prima financially healthy?
PT Royal Prima carries a debt-to-equity ratio of 0.00x and a current ratio of 2.17x, with a market beta of 0.20. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is PT Royal Prima a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For PT Royal Prima (PRIM) the key facts are: market cap Rp331.1B, revenue Rp338.9B, 52-week range 58-116. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track PT Royal Prima's full fundamentals live
Get PT Royal Prima's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.